GW&K Investment Management LLC Buys 91,054 Shares of AtriCure, Inc. $ATRC

GW&K Investment Management LLC increased its stake in AtriCure, Inc. (NASDAQ:ATRC) by 10.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 952,089 shares of the medical device company’s stock after acquiring an additional 91,054 shares during the quarter. GW&K Investment Management LLC owned 1.92% of AtriCure worth $37,665,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Aster Capital Management DIFC Ltd boosted its holdings in AtriCure by 197.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock worth $29,000 after acquiring an additional 538 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in AtriCure in the second quarter worth approximately $37,000. Global Retirement Partners LLC bought a new position in AtriCure in the fourth quarter worth approximately $73,000. State of Wyoming bought a new position in AtriCure in the fourth quarter worth approximately $75,000. Finally, Comerica Bank lifted its holdings in shares of AtriCure by 121.1% in the 4th quarter. Comerica Bank now owns 2,213 shares of the medical device company’s stock worth $88,000 after purchasing an additional 1,212 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

AtriCure Price Performance

Shares of NASDAQ:ATRC opened at $27.51 on Thursday. The company has a current ratio of 4.29, a quick ratio of 3.18 and a debt-to-equity ratio of 0.15. The stock’s fifty day simple moving average is $28.07 and its two-hundred day simple moving average is $33.14. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $43.18. The stock has a market cap of $1.39 billion, a PE ratio of -275.10 and a beta of 1.26.

Insiders Place Their Bets

In other AtriCure news, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total transaction of $85,950.00. Following the transaction, the director directly owned 26,373 shares in the company, valued at approximately $755,586.45. This trade represents a 10.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.00% of the company’s stock.

Analysts Set New Price Targets

ATRC has been the topic of a number of recent research reports. Oppenheimer cut AtriCure from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 18th. Wall Street Zen cut AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings cut AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. Citigroup reissued an “outperform” rating on shares of AtriCure in a research report on Wednesday, February 18th. Finally, Citizens Jmp decreased their target price on shares of AtriCure from $60.00 to $52.00 and set a “market outperform” rating for the company in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, AtriCure currently has an average rating of “Moderate Buy” and an average target price of $48.71.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.